Related Experiment Videos
A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and
S O Freytag1, K R Rogulski, D L Paielli
1Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202-3450, USA.
Abstract:
Two obstacles limiting the efficacy of nearly all cancer gene therapy trials are low gene transduction efficiencies and the lack of tumor specificity. Recently, a replication-competent, E1B-attenuated adenovirus (ONYX-015) was developed that could overcome these limitations, because it was capable of efficiently and selectively destroying tumor cells lacking functional p53. In an attempt to improve both the efficacy and safety of this approach, we constructed a similar adenovirus (FGR) containing a cytosine deaminase (CD)/herpes simplex virus type-1 thymidine kinase (HSV-1 TK) fusion gene, thereby allowing for the utilization of double-suicide gene therapy, which has previously been demonstrated to produce significant antitumor effects and potentiate the therapeutic effects of radiation. The FGR virus exhibited the same tumor cell specificity and replication kinetics as the ONYX-015 virus in vitro. Importantly, both the CD/5-FC and HSV-1 TK/GCV suicide gene systems markedly enhanced the tumor cell-specific cytopathic effect of the virus, and, as expected, sensitized tumor cells to radiation. By contrast, neither the FGR virus nor either suicide gene system showed significant toxicity to normal human cells. Both suicide gene systems could be used to suppress viral replication effectively, thereby providing a means to control viral spread. The results support the thesis that the three-pronged approach of viral therapy, suicide gene therapy, and radiotherapy may represent a powerful and safe means of selectively destroying tumor cells in vivo.
Insights
This study introduces a novel adenovirus (FGR) for cancer gene therapy, enhancing tumor cell destruction through combined viral, suicide gene, and radiation therapy. This approach shows improved efficacy and safety for cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer research
Background:
- Cancer gene therapy faces challenges with low transduction efficiency and tumor specificity.
- Adenovirus ONYX-015 selectively targets tumor cells lacking functional p53.
- Suicide gene therapy, using cytosine deaminase (CD)/herpes simplex virus type-1 thymidine kinase (HSV-1 TK), shows potent antitumor effects.
Purpose of the Study:
- To improve the efficacy and safety of oncolytic adenovirus therapy.
- To develop a novel adenovirus (FGR) combining viral therapy with double-suicide gene therapy (CD/HSV-1 TK).
- To evaluate the synergistic effects of FGR virus, suicide gene systems, and radiotherapy on tumor cells.
Main Methods:
- Construction of a replication-competent adenovirus (FGR) encoding a CD/HSV-1 TK fusion gene.
- In vitro assessment of FGR virus specificity and replication kinetics compared to ONYX-015.
- Evaluation of CD/5-FC and HSV-1 TK/GCV suicide gene systems in enhancing viral cytopathic effects and radiosensitization.
- Assessment of toxicity in normal human cells.
Main Results:
- FGR virus demonstrated similar tumor cell specificity and replication kinetics to ONYX-015 in vitro.
- Both CD/5-FC and HSV-1 TK/GCV systems significantly enhanced viral tumor cell killing and radiosensitization.
- Neither the FGR virus nor the suicide gene systems exhibited significant toxicity to normal human cells.
- Suicide gene systems effectively suppressed viral replication, enabling control of viral spread.
Conclusions:
- The combination of viral therapy, suicide gene therapy (CD/HSV-1 TK), and radiotherapy represents a potent and safe strategy for selective tumor cell destruction.
- The FGR virus, with its integrated suicide gene system, offers enhanced tumor-specific cytotoxicity and controllable viral spread.
- This multi-pronged approach holds significant promise for improving cancer treatment outcomes.